is frontline r-chop still the standard of care for dlbcl?
Published 2 years ago • 110 plays • Length 16:10Download video MP4
Download video MP3
Similar videos
-
1:26
can we improve on r-chop for the frontline treatment of dlbcl?
-
16:21
should r-chop remain the standard of care for dlbcl?
-
4:16
when will we be seeing changes in the frontline treatment of dlbcl?
-
2:18
the need for more effective, less toxic therapies in frontline dlbcl treatment
-
1:45
improving the frontline treatment of dlbcl
-
5:48
can frontline treatment of dlbcl be improved by combining novel agents with r-chop?
-
5:30
how the treatment landscape of dlbcl is changing: r-chop vs pola-r-chp
-
5:52
how do you approach the treatment of untreated dlbcl?
-
2:03
dr. poeschel on 6 versus 4 cycles of r-chop in frontline dlbcl
-
4:27
polarix: how does myc and bcl2 expression impact outcomes post frontline treatment with pv in dlbcl?
-
1:24
unmet needs remain in the diffuse large b-cell lymphoma treatment paradigm
-
2:44
polarix study: frontline therapy in dlbcl
-
14:57
how does the prognostic outlook for patients with double-hit lymphoma impact disease management?
-
6:38
what is the optimal frontline immunochemotherapy for primary mediastinal b-cell lymphoma?
-
0:53
dlbcl r chop remains the soc hd
-
5:05
what is the current standard of care for frontline treatment of chronic lymphocytic leukemia (cll)?
-
1:12
current treatment options for dlbcl besides r-chop chemotherapy
-
1:12
smart stop: moving away from r-chop in dlbcl
-
3:01
viola poeschel, md: 4 cycles of chop (instead of 6) is favorable for diffuse large b-cell lymphoma